Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Carnation Alsoy Concentrate infant formula recall

This article was originally published in The Tan Sheet

Executive Summary

Carnation Alsoy Concentrate infant formula recall: Nestle subsidiary announces recall of 500 cases (6,000 thirteen fluid ounce cans) of product distributed in Maryland, New York, New Jersey, Pennsylvania, Oklahoma, Texas and Virginia on Aug. 20. The firm has 320 of the cases under its control. The lids incorrectly state "Do Not Add Water" in English and French; ingestion of undiluted concentrated formula by infants could cause serious dehydration, diarrhea, cramping, vomiting and, over the course of several feedings, seizure and other life-threatening conditions. The lids were meant for ready-to-feed products to be exported to Canada, the firm said, adding that it has received several inquiries about the lids but no reports of undiluted use of the product...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel